Fred launches third-party apps market for pharmacies
Australian pharmacy IT options supplier Fred IT Group has launched an internet market of third-party purposes for pharmacies.
Referred to as Fred Market, the web-based hub has options which were authorised and examined to be used with Fred’s software program, together with apps and integrations for robots, eCommerce, enterprise intelligence, scientific companies, drug data and drugs administration, loyalty and fee.
Third-party options come from Fred’s trusted vendor companions, specifically BD, Dataology, GuildLink, LifeSmart, MIMs, Modeus, Storbie, StrongRoom, Tyro, and Willach Pharmacy Options.
{The marketplace} will proceed to carry on new software program companions and authorised purposes because it expands.
College of South Australia researchers develop fibre sensors to remotely monitor sufferers
Scientists from the College of South Australia have developed tiny optical fibre sensors to remotely monitor the positions of sufferers coping with painful stress sores in their beds.
“Every year, hundreds of older Australians in hospitals and nursing properties expertise stress accidents, or ulcers, which take a very long time to heal and might be deadly. On the very least, these accidents could cause extreme ache, disrupt sleep, have an effect on their temper, in addition to their rehabilitation, mobility and high quality of life,” mentioned Dr Stephen Warren-Smith, the lead researcher behind the brand new know-how.
The fibre sensors are connected to the higher floor of a mattress to watch motion and document coronary heart and respiratory charges.
By choosing up their respiratory, the unobtrusive sensors can detect when a affected person turns over, leaves a mattress, or stays immobile. Nurses might be prompted if a affected person has not moved for hours so they might alter their place.
Present strategies to watch sufferers coping with stress sores use weight-based sensors, which can not predict when a affected person leaves the mattress till their ft contact the ground. Digicam-based applied sciences are additionally getting used, though privateness is a serious concern.
EpiAxis Therapeutics, Peptilogics associate for AI drug discovery
Australian drug developer EpiAxis Therapeutics and Peptilogics, a US-based biotechnology firm, will harness AI in drug discovery to inhibit epigenetic oncology targets.
Their venture will make use of Peptilogics’ AI platform Nautilus, along with EpiAxis’s experience in epigenetics, to advance drug discovery for cancers that escape current therapies by epigenetic change, together with metastatic breast most cancers.
“We’ll concentrate on lead optimisation utilizing Peptilogics’ Nautilus platform, which mixes proprietary deep generative fashions, predictive fashions, and biophysical simulation to design multiparameter-optimised peptides with [the] potential to handle traditionally difficult and novel drug targets,” mentioned Peptilogics CTO Nicholas Nystrom.
This partnership follows EpiAxis’s lately concluded scientific trial which for the primary time has used an epigenetic inhibitor alongside chemotherapy to deal with metastatic most cancers.
